The position document summarized that the efficacy of DPP-4 inhibitors to lower glucose is intermediate when compared to other therapies, that DPP-4 inhibitors are neutral in relation to change in body weight, that major side effects are rarely seen for DPP-4 inhibitors, that the risk for hypoglycemia is low and that the cost is high. The gene discussed is DPP4; the disease is Hypoglycemia.